scholarly journals Chemotherapy Improves Survival After Percutaneous Biliary Drainage in Patients With Pancreatic or Biliary Tract Cancer With Biliary Obstruction

2021 ◽  
Vol 41 (6) ◽  
pp. 2979-2984
Author(s):  
JARMO NIEMELÄ ◽  
HANNU SYRJÄLÄ ◽  
PASI OHTONEN ◽  
JUHA SAARNIO ◽  
RAIJA KALLIO
Keyword(s):  
Biliary Tract ◽  
Biliary Tract Cancer ◽  
Biliary Drainage ◽  
Biliary Obstruction ◽  
Percutaneous Biliary Drainage ◽  
Tract Cancer

scholarly journals Predictive Factors of Chemotherapy Initiation after Biliary Drainage for Advanced Biliary Tract Cancer: A Retrospective Multicenter Study

2021 ◽  
Author(s):  
Miloud Azarfane ◽  
Astrid Lievre ◽  
Helene Senellart ◽  
Beatrice Desomme ◽  
Pauline Guillouche ◽  
...  
Keyword(s):  
Multivariate Analysis ◽  
Biliary Tract ◽  
Predictive Factors ◽  
Biliary Tract Cancer ◽  
Biliary Drainage ◽  
Biliary Obstruction ◽  
Male Gender ◽  
Biliary Tract Cancers ◽  
Tract Cancer ◽  
Chemotherapy Initiation

Background and Aims: In unresectable biliary tract cancers, the management of biliary obstruction is often the first step before introduction of chemotherapy. Our aim was to study the predictive factors of chemotherapy initiation after biliary drainage in a series of patients presenting with advanced biliary tract cancer and obstructive jaundice. Methods: Data of all patients treated for unresectable biliary tract cancer with initial biliary obstruction requiring a drainage in six institutions, from January 2009 to January 2019, were retrospectively collected. Results: Among 82 patients included in this study (median age 68 years, men 61%), 48 (59%) received chemotherapy. Median overall survival was 4.9 months (0.2-38.7) in the group of patients who did not receive chemotherapy and 12.2 months (1.9-61.0) in chemotherapy group (HR=2.93; 95%CI: 1.6-5.3; p<0.0001). In univariate analysis, younger age, male gender, Eastern Cooperative Oncology Group (ECOG) score ≤2, high albumin level, low C-reactive protein level, and endoscopic drainage were significantly associated with introduction of chemotherapy. In multivariate analysis, only ECOG score ≤2 at diagnosis (HR=70.4; 95%CI: 4.6-1097.6; p=0.002) and male gender (HR=5; 95%CI: 1.5-16.5; p=0.009), were significant independent predictive factors of chemotherapy introduction. Age and bilirubin level at diagnosis were not significant factors in multivariate analysis. Conclusions: ECOG score ≤ 2 and male gender were the only independent predictive factors of chemotherapy introduction in unresectable biliary tract cancers. Age or initial bilirubin level were not predictors for chemotherapy introduction. These results might help defining the initial therapeutic strategy.

Incidence and risk factors for cholangitis during systemic chemotherapy among patients with advanced biliary tract cancer.

2011 ◽  
Vol 29 (4_suppl) ◽  
pp. 313-313 ◽  
Author(s):  
J. Hashimoto ◽  
C. Morizane ◽  
S. Kondo ◽  
H. Ueno ◽  
S. Mitsunaga ◽  
...  
Keyword(s):  
Risk Factors ◽  
Median Time ◽  
Biliary Tract ◽  
Biliary Tract Cancer ◽  
Biliary Drainage ◽  
Systemic Chemotherapy ◽  
Sphincter Of Oddi ◽  
Ampullary Cancer ◽  
First Episode ◽  
Tract Cancer

313 Background: Patients with biliary tract cancer (BTC) have a high risk of developing cholangitis. In patients with advanced BTC receiving systemic chemotherapy, cholangitis might interfere with the execution of the treatment. Furthermore, cholangitis during severe immunosuppression might develop into lethal complications such as sepsis or shock. Purpose: To determine the incidence of cholangitis among patients with advanced BTC undergoing systemic chemotherapy and to identify risk factors for the development of cholangitis. Methods: We reviewed the records of 301 patients with advanced BTC who received systemic chemotherapy at our hospital between February 2002 and July 2009. The clinical data of patients treated with gemcitabine monotherapy (GEM) as a first-line chemotherapy was retrieved. Results: One hundred and thirty-one patients were successfully followed up throughout the entire GEM treatment. Forty-three patients had intrahepatic BTC (32.8%), 28 had extrahepatic BTC (21.4%), 11 had hilar BTC (8.4%), 7 had ampullary cancer (5.3%), and 42 had gallbladder cancer (32.1%). Interventional radiological treatment or biliary reconstruction for biliary obstruction was performed in 50 patients (37.9%) prior to the start of chemotherapy. The median time to GEM treatment failure was 126 days. Cholangitis developed in 30 patients (22.9%) during GEM, and severe cholangitis developed in 10 patients (7.6%). The median time to the first episode of cholangitis from the start of chemotherapy was 65 days. Chemotherapy was discontinued because of cholangitis in 4 patients (3.1%), but no deaths as a result of cholangitis occurred. A multivariate analysis using a logistic regression model demonstrated that the presence of hilar obstruction (p=0.0002, OR: 10.748), the loss of sphincter of Oddi function (p=0.0005,OR: 8.960), and the presence of internal biliary drainage (p=0.007, OR: 4.472) were independent risk factors of cholangitis. Conclusions: The incidence of cholangitis during GEM treatment was 22.9% among the advanced BTC patients in this study. Hilar obstruction, the loss of sphincter of Oddi function, and internal biliary drainage may be risk factors of cholangitis. No significant financial relationships to disclose.

Influence of obstructive jaundice on chemotherapy in patients with unresectable biliary tract cancer.

2014 ◽  
Vol 32 (3_suppl) ◽  
pp. 336-336
Author(s):  
Satoshi Shimizu ◽  
Shuichi Mitsunaga ◽  
Izumi Ohno ◽  
Hideaki Takahashi ◽  
Hiroyuki Okuyama ◽  
...  
Keyword(s):  
Overall Survival ◽  
Obstructive Jaundice ◽  
Biliary Tract ◽  
Biliary Tract Cancer ◽  
Biliary Obstruction ◽  
Chief Complaint ◽  
Tract Cancer ◽  
Group 2 ◽  
Line Chemotherapy ◽  
Group 1

336 Background: The aim of this study was to investigate the influences of obstructive jaundice (OJ) in unresectable biliary tract cancer (BTC) patients. Methods: Data of a total of 200 patients who were newly diagnosed as having unresectable BTC and received chemotherapy between July 2006 and December 2012 were retrospectively reviewed. Patients were divided into two groups according to whether or not they presented with OJ as the incipient chief complaint (Group 1, patients with OJ; Group 2, patients without OJ). Results: There were 81 patients in Group 1 and 119 patients in Group 2. In regard to the primary site (Group 1/Group 2), 29 had perihilar (27/2), 7 had distal (7/0), 68 had intrahepatic (15/53), 92 had gallbladder (31/61) and 4 had ampulla of vater (1/3) (p<0.01). The rate of distant metastasis was 60% in Group 1 and 76% in Group 2 (p=0.02). The performance status was good (0 or 1) in 96% of cases of both the groups. There were no significant differences in the median survival time between Group 1 and Group 2 (9.0 months vs. 9.0 months, p=0.42) or in the progression free survival of 1st line chemotherapy between the two groups (4.1 months vs. 3.7 months, p=0.08). The rate of development of biliary obstruction in Group 1 was significantly high during the first line chemotherapy (56% vs. 10%, p<0.01). Discontinuation of 1st line chemotherapy was necessitated due to biliary obstruction in 9 patients (10%) of Group 1 and none of the patients (0%) of Group 2. Multivariate analysis showed that absence of metastasis and use of a doublet chemotherapy regimen were significantly correlated with the overall survival, but not the presence of OJ as the incipient chief complaint (HR, 0.772; 95% CI, 0.532-1.119). Conclusions: Patients with OJ as the incipient chief complaint showed high rate of recurrent biliary obstruction and discontinuation chemotherapy due to biliary obstruction. However, OJ may not disadvantage for overall survival in BTC.

scholarly journals The outcomes of biliary drainage by percutaneous transhepatic cholangiography for the palliation of malignant biliary obstruction in England between 2001 and 2014: a retrospective cohort study

BMJ Open ◽  
2020 ◽  
Vol 10 (1) ◽  
pp. e033576 ◽  
Author(s):  
James Rees ◽  
Jemma Mytton ◽  
Felicity Evison ◽  
Kamarjit Singh Mangat ◽  
Prashant Patel ◽  
...  
Keyword(s):  
Biliary Tract ◽  
Biliary Drainage ◽  
Biliary Obstruction ◽  
Multivariate Logistic Regression Analysis ◽  
Percutaneous Transhepatic Cholangiography ◽  
Malignant Biliary Obstruction ◽  
Cancer Site ◽  
Tract Cancer ◽  
National Cohort ◽  
Poor Outcomes

IntroductionRelieving obstructive jaundice in inoperable pancreato-biliary cancers improves quality of life and permits chemotherapy. Percutaneous transhepatic cholangiography with drainage and/or stenting relieves jaundice but can be associated with significant morbidity and mortality. Percutaneous transhepatic biliary drainage (PTBD) in malignant biliary obstruction was therefore examined in a national cohort to establish risk factors for poor outcomes.MethodsRetrospective study of adult patients undergoing PTBD for palliation of pancreato-biliary cancer in England between 2001 and 2014 identified from Hospital Episode Statistics. Multivariate logistic regression analysis was used to examine associations with mortality and the need for a repeat PTBD within 2 months.Results16 822 patients analysed (median age 72 (range 19–104) years, 50.3% men). 58% pancreatic and 30% biliary tract cancer. In-hospital and 30-day mortality were 15.3% (95% CI 14.7% to 15.9%) and 23.1% (22.4%–23.8%), respectively. 20.2% suffered a coded complication within 3 months. Factors associated with 30-day mortality: age (≥81 years OR 2.68 (95% CI 2.37 to 3.03), p<0.001), increasing comorbidity (Charlson score 20+, 3.10 (2.64–3.65), p<0.001), pre-existing renal dysfunction (2.37 (2.12–2.65), p<0.001) and non-pancreatic cancer (unspecified biliary tract 1.28 (1.08–1.52), p=0.004). Women had lower mortality (0.91 (0.84–0.98), p=0.011), as did patients undergoing PTBD in a ‘higher volume’ provider (84–180 PTBDs per year 0.68 (0.58–0.79), p<0.001).ConclusionsIn patients undergoing PTBD for the palliation of malignant biliary obstruction, 30-day mortality was high at 23.1%. Mortality was higher in older patients, men, those with increasing comorbidity, a cancer site other than pancreas and at ‘lower-volume’ PTBD providers.

Preoperative biliary drainage-related inflammation is associated with shorter survival in biliary tract cancer patients

2016 ◽  
Vol 21 (5) ◽  
pp. 934-939 ◽  
Author(s):  
Hiroshi Kurahara ◽  
Kosei Maemura ◽  
Yuko Mataki ◽  
Masahiko Sakoda ◽  
Satoshi Iino ◽  
...  
Keyword(s):  
Cancer Patients ◽  
Biliary Tract ◽  
Biliary Tract Cancer ◽  
Biliary Drainage ◽  
Preoperative Biliary Drainage ◽  
Tract Cancer

scholarly journals Effect of biliary drainage on chemotherapy in patients with biliary tract cancer: an exploratory analysis of the BT22 study

HPB ◽  
2012 ◽  
Vol 14 (4) ◽  
pp. 221-227 ◽  
Author(s):  
Akira Fukutomi ◽  
Junji Furuse ◽  
Takuji Okusaka ◽  
Masaru Miyazaki ◽  
Masanori Taketsuna ◽  
...  
Keyword(s):  
Biliary Tract ◽  
Biliary Tract Cancer ◽  
Biliary Drainage ◽  
Exploratory Analysis ◽  
Tract Cancer

EGFR and HER2 Expression in advanced Biliary Tract Cancer

2008 ◽  
Vol 46 (09) ◽  
Author(s):  
J Harder ◽  
O Waiz ◽  
M Geissler ◽  
HE Blum ◽  
A Schmitt-Gräff ◽  
...  
Keyword(s):  
Biliary Tract ◽  
Biliary Tract Cancer ◽  
Her2 Expression ◽  
Tract Cancer
Sign in / Sign up

Export Citation Format

Share Document